These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 9414302)

  • 1. Lymphoma cell burden in progenitor cell grafts measured by competitive polymerase chain reaction: less than one log difference between bone marrow and peripheral blood sources.
    Léonard BM; Hétu F; Busque L; Gyger M; Bélanger R; Perreault C; Roy DC
    Blood; 1998 Jan; 91(1):331-9. PubMed ID: 9414302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone marrow versus peripheral blood progenitor cells CD34 selection in patients with non-Hodgkin's lymphomas: different levels of tumor cell reduction. Implications for autografting.
    Lopez M; Lemoine FM; Firat H; Fouillard L; Laporte JP; Lesage S; Isnard F; Stachowiak J; Ferrer-Le Coeur F; Morel P; Najman A; Douay L; Gorin NC
    Blood; 1997 Oct; 90(7):2830-8. PubMed ID: 9326252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of t(14;18) polymerase chain reaction-positive cells in highly purified CD34+ cells and their CD19 subsets in patients with follicular lymphoma.
    Voso MT; Hohaus S; Moos M; Haas R
    Blood; 1997 May; 89(10):3763-8. PubMed ID: 9160682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fate of contaminating t(14; 18)+ lymphoma cells during ex vivo expansion of CD34-selected hematopoietic progenitor cells.
    Widmer L; Pichert G; Jost LM; Stahel RA
    Blood; 1996 Oct; 88(8):3166-75. PubMed ID: 8874217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis.
    Kanteti R; Miller K; McCann J; Roitman D; Morelli J; Hurley C; Berkman E; Schenkein D
    Bone Marrow Transplant; 1999 Sep; 24(5):473-81. PubMed ID: 10482930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Occult lymphoma cells prevalent in autologous marrow from non-Hodgkin's diffuse lymphoma.
    Yokoyama J; Fujimiya Y; Yamaguchi T; Shiga K; Saijo Y; Groveman DS; McBain JA; Suzuki Y; Ebina T
    Am J Hematol; 2003 May; 73(1):1-11. PubMed ID: 12701113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-Hodgkin's lymphoma.
    Negrin RS; Kusnierz-Glaz CR; Still BJ; Schriber JR; Chao NJ; Long GD; Hoyle C; Hu WW; Horning SJ; Brown BW
    Blood; 1995 Jun; 85(11):3334-41. PubMed ID: 7538824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts.
    Dreger P; Klöss M; Petersen B; Haferlach T; Löffler H; Loeffler M; Schmitz N
    Blood; 1995 Nov; 86(10):3970-8. PubMed ID: 7579368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A non-isotopic nested polymerase chain reaction method to quantitate minimal residual disease in patients with non-Hodgkin's lymphoma.
    Hétu F; Coutlée F; Roy DC
    Mol Cell Probes; 1994 Dec; 8(6):449-57. PubMed ID: 7700265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow.
    Gribben JG; Neuberg D; Barber M; Moore J; Pesek KW; Freedman AS; Nadler LM
    Blood; 1994 Jun; 83(12):3800-7. PubMed ID: 8204898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiplex PCR for the detection of BCL-1/IGH and BCL-2/IGH gene rearrangements--clinical validation in a prospective study of blood and bone marrow in 258 patients with or suspected of non-Hodgkin's lymphoma.
    Nyvold CG; Bendix K; Brandsborg M; Pulczynski S; Silkjaer T; Hokland P
    Acta Oncol; 2007; 46(1):21-30. PubMed ID: 17438702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eradication of polymerase chain reaction detectable immunoglobulin gene rearrangement in non-Hodgkin's lymphoma is associated with decreased relapse after autologous bone marrow transplantation.
    Zwicky CS; Maddocks AB; Andersen N; Gribben JG
    Blood; 1996 Nov; 88(9):3314-22. PubMed ID: 8896395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [BCL-2/IgH and IgH gene rearrangements in bone marrow mononuclear cells of patients with non-Hodgkin's lymphoma].
    Zhang XH; Liang Y; Wang GJ; Ruan EB; Fu R; Qu W; Liu H; Guan J; Song J; Wang HQ; Wu YH; Xing LM; Wang XM; Wang J; Li LJ; Shao ZH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Apr; 19(2):379-84. PubMed ID: 21518492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential high-dose therapy with peripheral-blood progenitor-cell support in low-grade non-Hodgkin's lymphoma.
    Haas R; Moos M; Karcher A; Möhle R; Witt B; Goldschmidt H; Frühauf S; Flentje M; Wannenmacher M; Hunstein W
    J Clin Oncol; 1994 Aug; 12(8):1685-92. PubMed ID: 7518860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
    Lemoli RM; Cavo M; Fortuna A
    J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting.
    Corradini P; Astolfi M; Cherasco C; Ladetto M; Voena C; Caracciolo D; Pileri A; Tarella C
    Blood; 1997 Jan; 89(2):724-31. PubMed ID: 9002976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymerase chain reaction detection of cells carrying t(14;18) in bone marrow of patients with follicular and diffuse large B-cell lymphoma: the importance of analysis at diagnosis and significance of long-term follow-up.
    Papajík T; Jedlicková K; Kriegová E; Jarosová M; Raida L; Faber E; Hubácek J; Vondráková J; Pikalová Z; Indrák K
    Neoplasma; 2001; 48(6):501-5. PubMed ID: 11949845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment.
    Gribben JG; Freedman As; Woo SD; Blake K; Shu RS; Freeman G; Longtine JA; Pinkus GS; Nadler LM
    Blood; 1991 Dec; 78(12):3275-80. PubMed ID: 1742487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of tumor cells in purged bone marrow and peripheral-blood mononuclear cells by polymerase chain reaction amplification of bcl-2 translocations.
    Negrin RS; Pesando J
    J Clin Oncol; 1994 May; 12(5):1021-7. PubMed ID: 8164025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MBR rearrangement and P-glycoprotein expression are not independent prognostic factors like p53 protein in malignant lymphoma.
    Sun RX; Coste J; Segara C; Rousset T; Fabbro M; Rème T; Legouffe E; Klein B; Rossi JF
    Clin Lab Haematol; 1998 Apr; 20(2):87-94. PubMed ID: 9681218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.